Mild cognitive impairment is an early stage of cognitive decline greater than expected for age while most daily functional independence is preserved. It may remain stable, improve, or progress to dementia depending on etiology and risk profile.
Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
New research demonstrates that blood tests measuring p-tau217 protein can identify dementia risk up to 25 years before symptoms and significantly improve diagnostic accuracy in clinical practice.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602283 |
Music for Pain and Dementia |
RECRUITING | NA |
| NCT07596940 |
A Health Game Intervention for Cancer and Post-ICU Patients Suffering From Acute Cognitive Impairment |
COMPLETED | NA |
| NCT07579689 |
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment |
NOT_YET_RECRUITING | PHASE4 |
| NCT07554144 |
The Effect of Body Percussion Training on Neuromotor Performance, Attention, and Functionality in Adolescents With Mild Intellectual Disability |
NOT_YET_RECRUITING | NA |
| NCT07548073 |
Effect of Scene-Based Training on Cognitive Function in Patients With Alzheimer's Disease |
COMPLETED | NA |
| NCT07534878 |
Health Benefits of Nutraceutical Supplementation in Older Adults. |
COMPLETED | PHASE4 |
| NCT07521865 |
Remote Technologies in Early Stages of Alzheimer's Disease |
ACTIVE_NOT_RECRUITING | |
| NCT07512362 |
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07511270 |
Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech |
RECRUITING | NA |
| NCT07504965 |
Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly |
RECRUITING |
